

**Unaudited Financial Statements**  
**For The Year Ended 31 December 2020**  
**for**  
**ARISE PHARMA LTD**

**Contents of the Financial Statements**  
**For The Year Ended 31 December 2020**

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Balance Sheet</b>	<b>2</b>
<b>Notes to the Financial Statements</b>	<b>4</b>

**ARISE PHARMA LTD**

**Company Information**

**For The Year Ended 31 December 2020**

**DIRECTORS:**

Mrs M Jaykumar Jani  
V B Soni  
J Pradyuman Jani

**SECRETARY:**

J Pradyuman Jani

**REGISTERED OFFICE:**

79 College Road  
Harrow  
Middlesex  
Middlesex  
HA1 1BD

**REGISTERED NUMBER:**

08629933 (England and Wales)

**ACCOUNTANTS:**

Ayman Tyler Associates  
Accountants & Tax Advisers  
79 College Road  
Harrow  
Middlesex  
HA1 1BD

**ARISE PHARMA LTD (REGISTERED NUMBER: 08629933)****Balance Sheet**  
**31 December 2020**

	Notes	31.12.20 £	£	31.12.19 £	£
<b>FIXED ASSETS</b>					
Tangible assets	4		1,637		590
Investments	5		<u>241,460</u>		<u>245,910</u>
			<b>243,097</b>		<b>246,500</b>
<b>CURRENT ASSETS</b>					
Debtors	6	298,842		453,891	
Cash at bank		<u>556</u>		<u>184</u>	
		<b>299,398</b>		<b>454,075</b>	
<b>CREDITORS</b>					
Amounts falling due within one year	7	<u>331,812</u>		<u>383,731</u>	
<b>NET CURRENT (LIABILITIES)/ASSETS</b>			<b>(32,414)</b>		<b>70,344</b>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<b>210,683</b>		<b>316,844</b>
<b>CREDITORS</b>					
Amounts falling due after more than one year	8		<u>50,000</u>		<u>-</u>
<b>NET ASSETS</b>			<b>160,683</b>		<b>316,844</b>
<b>CAPITAL AND RESERVES</b>					
Called up share capital			1,000		1,000
Retained earnings			<u>159,683</u>		<u>315,844</u>
<b>SHAREHOLDERS' FUNDS</b>			<b>160,683</b>		<b>316,844</b>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

**Balance Sheet - continued**  
**31 December 2020**

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 August 2021 and were signed on its behalf by:

Mrs M Jaykumar Jani - Director

J Pradyuman Jani - Director

**Notes to the Financial Statements**  
**For The Year Ended 31 December 2020**

**1. STATUTORY INFORMATION**

ARISE PHARMA LTD is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 33% on cost

**Investments in associates**

Investments in associate undertakings are recognised at cost.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 2 (2019 - 2 ) .

**Notes to the Financial Statements - continued**  
**For The Year Ended 31 December 2020**

**4. TANGIBLE FIXED ASSETS**

	<b>Plant and machinery etc £</b>
<b>COST</b>	
At 1 January 2020	1,736
Additions	<u>1,996</u>
At 31 December 2020	<u>3,732</u>
<b>DEPRECIATION</b>	
At 1 January 2020	1,146
Charge for year	<u>949</u>
At 31 December 2020	<u>2,095</u>
<b>NET BOOK VALUE</b>	
At 31 December 2020	<u>1,637</u>
At 31 December 2019	<u>590</u>

**5. FIXED ASSET INVESTMENTS**

	<b>31.12.20 £</b>	31.12.19 £
Participating interests	18,110	18,110
Loans to undertakings in which the company has a participating interest	<u>223,350</u>	<u>227,800</u>
	<u><b>241,460</b></u>	<u><b>245,910</b></u>

Additional information is as follows:

	<b>Interest in associate £</b>
<b>COST</b>	
At 1 January 2020 and 31 December 2020	<u>18,110</u>
<b>NET BOOK VALUE</b>	
At 31 December 2020	<u>18,110</u>
At 31 December 2019	<u>18,110</u>
	<b>Loans to associates £</b>
At 1 January 2020	227,800
New in year	<u>(4,450)</u>
At 31 December 2020	<u><b>223,350</b></u>

**Notes to the Financial Statements - continued**  
**For The Year Ended 31 December 2020****5. FIXED ASSET INVESTMENTS - continued**

The company currently holds 18,000 Ordinary shares of £1 each, representing an 18% Investment in the company Liqmeds Limited and 110 Ordinary shares of £1 each, representing a 22% Investment in the company Ace Laboratories Limited.

The loans to Associates relates to loans to Ace Laboratories Ltd.

**6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.20	31.12.19
	£	£
Trade debtors	-	120,000
Other debtors	<u>298,842</u>	<u>333,891</u>
	<u>298,842</u>	<u>453,891</u>

Other Debtors balance includes £216,183 loan to LM Manufacturing Ltd, £3,959 expenses paid on behalf of LM Manufacturing Ltd, £67,500 loan to JAJ Pharma Ltd and £10,000 loan to Liqmeds Limited.

**7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.20	31.12.19
	£	£
Taxation and social security	14,830	25,089
Other creditors	<u>316,982</u>	<u>358,642</u>
	<u>331,812</u>	<u>383,731</u>

Included in Other Creditors is an amount of £44,365 being loan from company Wave Pharma Ltd, £253,440 Director's Current Account credit balance for Mr V B Soni and £17,752 Director's Current Account credit balance for Mrs M Jani.

**8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	31.12.20	31.12.19
	£	£
Bank loans (see note 9)	<u>50,000</u>	<u>-</u>

**9. LOANS**

An analysis of the maturity of loans is given below:

	31.12.20	31.12.19
	£	£
Amounts falling due between two and five years:		
Bank loans - 2-5 years	<u>50,000</u>	<u>-</u>

The company received a government backed bounce back loan for £50,000 on 17th August 2020.



This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.